Reduction of mortality by catheter ablation in real-world atrial fibrillation patients with heart failure by 김대훈 et al.
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4694  | https://doi.org/10.1038/s41598-021-84256-z
www.nature.com/scientificreports
Reduction of mortality by catheter 
ablation in real‑world atrial 
fibrillation patients with heart 
failure
Pil‑Sung Yang1,3, Daehoon Kim2,3, Jung‑Hoon Sung1, Eunsun Jang2, Hee Tae Yu2, 
Tae‑Hoon Kim2, Jae‑Sun Uhm2, Jong‑Youn Kim2, Hui‑Nam Pak2, Moon‑Hyoung Lee2 & 
Boyoung Joung2*
Whether catheter ablation for atrial fibrillation (AF) improves survival and affects other outcomes 
in real‑world heart failure (HF) patients is unclear. This study aimed to evaluate whether ablation 
reduces death, and other outcomes in real‑world AF patients with HF. Among 834,735 patients with 
AF from 2006 to 2015 in the Korean National Health Insurance Service database, 3173 HF patients 
underwent AF ablation. Propensity score weighting was used to correct for differences between 
the groups. During median 54 months follow‑up, the risk of all‑cause death in ablated patients was 
less than half of that in patients with medical therapy (2.8 vs. 6.2 per 100 person‑years; hazard ratio 
[HR] 0.42, 95% confidence interval [CI] 0.27–0.65, p < 0.001). Ablation was related with lower risk of 
cardiovascular death (HR 0.38, 95% CI 0.32–0.62, p < 0.001), HF admission (HR 0.39, 95% CI 0.33–0.46, 
p < 0.001) and stroke/systemic embolism (HR 0.44, 95% CI 0.37–0.53, p < 0.001). In subgroup analysis, 
the risk of all‑cause death was reduced in most subgroups except in the elderly (≥ 75 years) and 
strictly anticoagulated patients. Ablation may be associated with reduced risk of all‑cause death and 
cardiovascular death in real‑world AF patients with HF, supporting the role of AF ablation in patients 
with HF.
Atrial fibrillation (AF) and heart failure are important cardiac conditions associated with the patient’s morbidity 
and  mortality1,2. The two conditions often coexist and can promote each other. Up to 30% of patients with heart 
failure have  AF3–5. AF in patients with heart failure is associated with increased hospitalization, the burden on 
the health care system, stroke, and  mortality6,7. Loss of atrial contraction, irregular and rapid ventricular rates 
in AF can lead to left ventricular dysfunction and decreased cardiac  output8,9, and these features of AF may be 
at least partially contributed to poor prognosis of heart failure patients.
Catheter ablation for AF is more effective than antiarrhythmic drugs (AADs) in reducing AF recurrences; 
AF catheter ablation also extends the duration of the sinus rhythm and improves the patient’s quality of  life10,11. 
Several observational studies have shown that maintaining sinus rhythm by AF catheter ablation in heart fail-
ure patients can significantly improve cardiac  function12–14. Recently, a trial evaluating ablation compared with 
medical therapy in symptomatic patients with AF and heart failure provided evidence suggesting that success-
ful ablation may extend  survival15. However, because only 13.2% of the screened heart failure patients were 
enrolled in randomization in the study, the effect of AF ablation in heart failure patients is still controversial. 
In the CABANA (Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial, the recently 
performed randomized controlled trial on the effects of AF catheter  ablation16, AF catheter ablation did not 
significantly reduce the primary endpoint (a composite of death, disabling stroke, serious bleeding, or cardiac 
arrest) compared to medical treatment.
Our study aimed to determine whether AF catheter ablation in heart failure patients can reduce the risk of 
all-cause death, cardiovascular death, and other cardiac events in a real-world nationwide cohort.
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Methods
This study was based on the national health claims database (NHIS-2016-4-009) established by the National 
Health Insurance Service (NHIS) of Korea. The NHIS is the single insurer managed by the Korean government. 
The majority (97.1%) of Korean citizens are mandatory subscribers to the NHIS, and the remaining 3% of the 
population is under the Medical Aid program. As the NHIS database contains the information of Medical Aid 
users, the database can be considered to be representative of the entire Korean  population3–5. All pertinent data 
including patients’ sociodemographic information, use of inpatient and outpatient services, pharmacy-dispensing 
claims, and mortality can be accessed through this database. The NHIS also runs a regular health check-up 
program for all citizens. NHIS subscribers are recommended to undergo check-ups at least biennially, and the 
check-up includes blood tests, chest X-ray, physical examinations, and questionnaires for medical history.
The present study was approved by the Institutional Review Board of Yonsei University Health System 
(4-2016-0179). The board waived the condition of obtaining informed consent for study participation. All meth-
ods included in this study were carried out in accordance with relevant guidelines and regulations.
Study population. From January 1, 2006, to December 31, 2015, 834,735 adult patients (18  years old) 
newly diagnosed with AF were identified in the Korean NHIS database covering a population of 51.5 million. AF 
was confirmed by the diagnostic code (International Classification of Disease 10th revision [ICD-10] code: I48). 
Only patients who were diagnosed during hospitalization or diagnosed at least two times in an outpatient clinic 
were confirmed as AF to ensure the accuracy of the diagnosis. The accuracy of this definition has already been 
validated in previous studies using the Korean NHIS data. A positive predictive value was 94.1%3–5,17–19. From 
newly diagnosed AF patients, patients treated with AF catheter ablation or medical therapy (AADs or rate con-
trol drugs prescribed for at least 90 days within one year of enrollment) were included in the study population. 
Catheter ablation for AF was identified using the corresponding Korean NHIS procedure codes for AF catheter 
ablation (M6542 or M6547) with an admission diagnosis of AF.
The time at risk was counted from the index date of the first AF treatment for both patients with AF ablation 
and those with medical therapy. The time at risk in patients who underwent AF ablation without prior medical 
treatment was counted from the date of the first AF ablation. The effect of AF ablation was analyzed as a time-
varying exposure. The exclusion criteria were those with mitral stenosis, a history of mitral valve replacement, 
surgical AF ablation (Maze surgery), or implantation of cardiac implantable electronic device, and those without 
heart failure history. Patients who had oral anticoagulants less than 30 days during the same period were addi-
tionally excluded from the medical therapy group. After exclusions, 3173 ablated patients and 12,058 medically 
treated patients remained for analysis (Fig. 1).
Covariates. Baseline comorbidities were defined based on inpatient and outpatient clinic diagnosis and pre-
scription drugs prior to the index date. Similar to previous studies using Korean NHIS data, patients diagnosed 
in admission or confirmed at least twice in an outpatient clinic were considered to have a comorbid (Supplemen-
tary Table S1)3–5,17–19. The patient’s economic status was determined on the basis of the relative economic level 




Patients who received ablation or 
medical therapy (n=194,928)
Valvular AF (n=19,501)
Patients who did not receive 
any treatment (n=639,807)
Medical therapy (n=12,058)
OAC < 30 days (n=7,364)
Medical therapy (n=184,902)
Arrhythmia surgery (n=66)  
Pacemaker or ICD (n=216) 
No heart failure (n=6,249)  
Arrhythmia surgery (n=659) 
Pacemaker or ICD (n=2,698) 
No heart failure (n=142,622)
Figure 1.  Flowchart of the enrollment and analysis of the study population. AF, atrial fibrillation; ICD, 
implantable cardioverter-defibrillator; OAC, oral anticoagulant.
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classified into 10 tiers according to their health insurance premium of the index year. The use of medication was 
identified based on prescription claims in the NHIS database within 90 days prior to the index date.
Clinical outcome events and assessments. To assess clinical outcomes, patients were followed until 
the end of the study period (December 31, 2016) or until death. All-cause death, cardiovascular death, and 
sudden cardiac death were evaluated. Vital status and the date of death were identified from the data registered 
in the National Population Registry of the Korea National Statistical Office, based on death certificates and 
the unique personal identification  number3–5,17–19. Since the NHIS and National Statistical Office are national 
organizations covering all Korean citizens, this approach allows complete confirmation of death events.
The definitions of clinical outcomes are presented in Supplementary Table S1. Ischemic stroke was identi-
fied by discharge diagnosis (ICD-10 codes: I63, I64) with concomitant brain imaging studies. The accuracy of this 
definition for ischemic stroke has been validated in previous studies using the Korean NHIS  data3–5,17–19. It must 
be noted that only the first event of each outcome was considered in the study when there are multiple events.
To indirectly assess the relationship between successful rhythm control by ablation and outcomes, we con-
sidered “Cardioversion or repeated ablation” as an indicator of AF recurrence after ablation. We also performed 
a validation study of this definition for detecting AF recurrence (Supplement Figure S1).
Statistical methods. Baseline characteristics between patients with AF ablation and those with medical 
therapy were compared using Student’s t-test and chi-square test. A propensity score, the probability of receiving 
AF ablation, was estimated using logistic regression based on socio-demographics, concomitant diseases, drug 
use, and duration of AF. (All variables in Table 1 were used). On the basis of the calculated propensity score, 
inverse probability of treatment weighting was used to balance the differences in baseline characteristics between 
patients with AF ablation and those with medical therapy. The balance between the two groups was assessed with 
standardized differences of all baseline covariates, using 0.1 as the threshold representing the imbalance.
Weighted incidence rates were calculated as the weighted number of clinical events during the follow-up 
period divided by person-years at risk. The 95% confidence intervals (CI) of incidence rates were estimated 
by exact Poisson distributions. A weighted log-rank test was used to compare the incidence of mortality and 
weighted failure curves were plotted. Comparisons between the ablation group and the medical therapy group 
were analyzed using Cox proportional hazards regressions. The Fine and Gray method was used to regard death 
as a competing risk when evaluated non-fatal outcomes (i.e. heart failure and stroke/systemic embolism (SE) 
when evaluated separately)20. The proportional hazards assumption was tested based on Schoenfeld  residuals21.
A two-sided p values of < 0.05 were considered significant. Data processing and management were performed 
using SAS version 9.3 (SAS Institute, Cary, NC, USA). Statistical analyses were conducted using R software (ver-
sion 3.6.1, R Core Team, 2019, Vienna, Austria)22.
Sensitivity analyses. First, we conducted subgroup analyses for all-cause death and cardiovascular death 
stratified by age, sex, heart failure, hypertension, diabetes, vascular disease,  CHA2DS2-VASc score, history of 
ischemic stroke/transient ischemic attack (TIA), cardioversion, and anticoagulation. Second, instead of using 
propensity score weighting, we performed an analysis using one-to-one propensity score matching between 
groups to balance the differences in baseline characteristics. Third, we performed a stratified analysis according 
to whether medically treated patients were treated with AADs or only with rate control drugs. Fourth, we com-
pared heart failure patients who underwent AF ablation and those who did not have a history of AF. Fifth, we 
performed “falsification analysis” to determine whether AF ablation was associated with the risks of falsification 
endpoints such as urinary tract infections, Varicella-zoster, and fall accidents, which should not be associated 
with AF  ablation23.
Results
Differences between ablated and the non‑ablated patients. Patients treated with AF catheter abla-
tion had more men, healthier, and higher incomes than those who were medically treated (Table 1). Compared 
with non-ablated patients, patients receiving ablation were on average 10 years younger and had fewer comor-
bidities. After propensity score weighting, no significant differences in baseline characteristics were observed 
between the two groups (Table 1). In multivariable analysis, patients with younger age, higher income, and fewer 
comorbidities (especially without diabetes, ischemic stroke/TIA, myocardial infarction, and peripheral artery 
disease) were more likely to undergo AF ablation (Supplementary Table S2).
Patients who underwent AF ablation were younger and healthier than AAD treated (Supplementary Table S3) 
and rate control patients (Supplementary Table S4). After propensity score weighting, no significant differences 
in baseline characteristics were observed between the groups.
Reduced all‑cause and cardiovascular death in ablated patients. In propensity score-weighted 
patients, 394 and 3940 all-cause deaths occurred during the median 54 (interquartile ranges: 19, 80) months 
follow-up period, and weighted annualized rates of all-cause death were 2.8 and 6.2 per 100 person-years in 
the ablated and medical therapy group, respectively (p < 0.001) (Table 2). The cumulative incidence of all-cause 
death in patients with AF ablation was significantly lower than those with medical therapy (p < 0.001, Fig. 2A). 
After fully adjusting the available clinical parameters, the risk of all-cause death was reduced by 58% in ablated 
patients compared to patients receiving medical therapy (hazard ratio [HR] 0.42, 95% CI 0.27–0.65, p < 0.001) 
(Table 2). The risk of all-cause mortality was reduced in patients with AF ablation compared to those treated 
with AAD (HR 0.49, 95% CI 0.34–0.71, p < 0.001) and rate control only (HR 0.39, 95% CI 0.27–0.57, p < 0.001) 
(Table 2). Subgroup analyses found a reduction in the risk of all-cause death in most subgroups, except for the 
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4694  | https://doi.org/10.1038/s41598-021-84256-z
www.nature.com/scientificreports/
Ablation (N = 3173)
Medical therapy 
(N = 12,058) SMD (%) Ablation (N = 3173)
Medical therapy 
(N = 12,058) SMD (%)
Demographic
Age, years 60 (53, 67) 69 (62, 76) 82.2 66 (58, 74) 66 (58, 74) 0.9
 < 65 years 67.4% 33.4% 72.2 42.8% 44.2% 2.8
 65–75 yearswprk dl 26.3% 32.7% 14.1 29.9% 30.4% 1.0
 ≥ 75 years 4.8% 30.3% 71.0 24.0% 22.5% 3.5
Male 71.5% 59.1% 26.3 64.5% 62.7% 3.7
High income status 51.7% 42.1% 19.2 49.2% 44.3% 9.8
AF duration, months 34.9 (11.9, 66.8) 23.6 (4.6, 46.0) 29.6 20.1 (5.2, 49.5) 23.4 (3.9, 48.7) 5.1
Risk scores
CHA2DS2-VASc 
score 3.0 (2.0, 5.0) 5.0 (3.0, 6.0) 73.0 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 2.9
mHAS-BLED score* 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 36.3 1.4 (0.8, 2.7) 3.0 (2.1, 3.9) 5.3
Charlson comorbid-
ity index 1.8 (0.0, 4.8) 3.2 (0.0, 8.8) 38.7 5.0 (3.0, 7.0) 5.0 (3.0, 7.0) 1.1
Hospital frailty risk 
score 4.0 (3.0, 6.0) 5.0 (3.0, 8.0) 62.6 2.9 (0.7, 6.3) 2.3 (0.0, 7.1) 9.0
Comorbidities
Heart failure 100.0% 100.0% < 0.001 100.0% 100.0% < 0.1
Hypertension 91.3% 94.7% 13.4 93.9% 92.7% 4.6
Diabetes 17.8% 31.1% 31.3 27.5% 27.0% 1.1
Dyslipidemia 88.5% 80.0% 23.6 83.4% 81.5% 5.0
Ischemic stroke 19.9% 36.1% 36.8 32.9% 30.7% 4.7
TIA 10.1% 11.1% 3.4 10.0% 10.7% 2.5
Hemorrhagic stroke 1.5% 3.4% 12.7 4.8% 2.8% 10.2
Myocardial infarc-
tion 13.6% 21.0% 19.7 17.3% 18.5% 3.1
Peripheral arterial 
disease 14.2% 18.0% 10.3 15.1% 16.7% 4.3
Chronic kidney 
disease 5.9% 10.1% 15.4 11.2% 8.8% 8.1
End stage renal 
disease 0.9% 1.5% 5.7 1.4% 1.3% 1.0
Proteinuria 5.9% 6.6% 2.9 6.5% 6.4% 0.6
Hyperthyroidism 23.2% 17.4% 14.5 17.9% 18.4% 1.3
Hypothyroidism 20.6% 14.6% 15.6 13.9% 15.5% 4.6
Malignancy 21.9% 22.8% 2.0 18.9% 22.1% 7.9
COPD 26.2% 38.5% 26.7 36.9% 34.5% 5.1
Liver disease 49.4% 43.4% 12.0 43.7% 44.6% 1.8
Hypertrophic cardio-
myopathy 3.3% 4.0% 3.7 3.9% 3.8% 0.7
History of bleeding 33.6% 33.7% 0.3 35.9% 33.4% 5.4
Osteoporosis 20.9% 31.1% 23.4 26.0% 27.9% 4.4
Sleep apnea 2.1% 0.5% 14.4 1.3% 0.9% 3.8
Heart failure admis-
sion 7.5% 27.2% 54.0 22.3% 22.3% < 0.1
Medication (treat-
ment) 0.0% 0.0% 0.0% 0.0%
OAC 68.2% 76.6% 18.9 63.3% 68.9% 12.0
Antiplatelet agents 79.8% 70.6% 21.4 70.6% 71.5% 2.0
ACE-inhibitor/ARB 64.2% 74.4% 22.2 72.5% 70.2% 5.0
Diuretics 53.7% 76.7% 49.6 70.5% 69.3% 2.7
K sparing diuretics 17.5% 34.8% 40.3 29.6% 29.2% 1.0
Statin 46.9% 43.1% 7.6 45.2% 43.1% 4.3
Beta blocker 77.0% 65.3% 25.9 67.1% 66.7% 0.8
Dihydropyridine 
CCB 34.7% 42.5% 16.1 43.3% 40.0% 6.7
Nondihydropyridine 
CCB 27.2% 20.1% 16.6 20.9% 21.1% 0.6
Digoxin 23.5% 45.0% 46.6 37.6% 38.7% 2.3
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elderly (≥ 75 years) and optimally anticoagulated (proportion of days covered by anticoagulant ≥ 80%) patients 
(Fig. 3).
The risk of cardiovascular death was 62% lower (1.2 and 3.0 per 100 person-years, respectively; HR 0.38, 95% 
CI 0.32–0.62, p < 0.001), and the cumulative incidence of cardiovascular death was significantly lower in patients 
with AF ablation compared to those with medical therapy (p < 0.001) (Table 2, Fig. 2B). The risk of cardiovascular 
mortality was also reduced in patients with AF ablation compared to those treated with AAD (HR 0.43, 95% CI 
0.27–0.68, p < 0.001) and rate control only (HR 0.35, 95% CI 0.22–0.56, p < 0.001) (Table 2). Subgroup analyses 
about the risk of cardiovascular death showed that it was reduced in most subgroups except in heart failure 
patients without hypertension and those with vascular disease (Fig. 4).
Table 1.  Baseline characteristics before and after propensity score weighting. Values are presented as median 
(Q1, Q3, quartiles [25th and 75th percentiles]) or %. *Modified HAS-BLED = hypertension, 1 point: > 65 years 
old, 1 point: stroke history, 1 point: bleeding history or predisposition, 1 point: liable international normalized 
ratio, not assessed: ethanol or drug abuse, 1 point: drug predisposing to bleeding, 1 point. ACE angiotensin 
converting enzyme, AF atrial fibrillation, ARB angiotensin II receptor blocker, CCB calcium channel blocker, 
COPD chronic obstructive pulmonary disease, OAC oral anticoagulant, SMD standardized mean difference, 
TIA transient ischemic attack.
Table 2.  Risk of clinical outcomes in propensity score-weighted patients stratified by treatment. *Adjusted 
for age, sex, income, AF duration,  CHA2DS2-VASc score, modified HAS-BLED score, hospital frailty risk 
score, Charlson comorbidity index, hypertension, diabetes, ischemic stroke/TIA, myocardial infarction, 
peripheral arterial disease, hypertrophic cardiomyopathy, chronic kidney disease, end stage renal disease, 
liver disease, malignancy, hyperthyroidism, hypothyroidism, venous thromboembolism, COPD, intracranial 
bleeding, previous cardioversion, history of bleeding, baseline use of warfarin, non-vitamin K antagonist oral 
anticoagulant, aspirin, clopidogrel, beta-blocker, ACE-inhibitor/ARB, dihydropyridine/nondihydropyridine 
CCB, statin, diuretics, digoxin, and OAC coverage rate of time at risk. AAD antiarrhythmic drug, CI 
confidence interval, SE systemic embolism. Other abbreviations are same as Table 1.
Number of 
events Person years








event rate (95% 
CI)
Hazard ratio 
(95% CI) * p value
Ablation vs. medical therapy
Medical Therapy (N = 12,058) Ablation (N = 3173)
All-cause death 3940 63,486 6.2 394 14,155 2.8 3.4 (3.0–3.9) 0.42 (0.27–0.65) < 0.001
Cardiovascular 
death 1912 63,486 3.0 174 14,155 1.2 1.8 (1.5–2.1) 0.38 (0.22–0.62) < 0.001
Heart failure 2540 54,200 4.7 273 12,937 2.1 2.6 (2.2–3.0) 0.39 (0.33–0.46) < 0.001
Stroke/SE 2057 56,534 3.6 301 13,130 2.3 1.3 (1.0–1.7) 0.44 (0.37–0.53) < 0.001
Sudden cardiac 
death 601 62,868 1.0 65 14,064 0.5 0.5 (0.3–0.7) 0.47 (0.19–1.18) 0.108
Ablation vs. AAD treated
AAD treated (N = 7976) Ablation (N = 3173)
All-cause death 2047 42,158 4.9 345 14,352 2.4 2.5 (2.1–2.8) 0.49 (0.34–0.71) < 0.001
Cardiovascular 
death 977 42,158 2.3 153 14,352 1.1 1.3 (1.0–1.5) 0.43 (0.27–0.68) < 0.001
Heart failure 1574 36,520 4.3 256 13,171 1.9 2.4 (2.0–2.7) 0.35 (0.30–0.42) < 0.001
Stroke/SE 1222 38,261 3.2 281 13,370 2.1 1.1 (0.8–1.4) 0.45 (0.37–0.54) 0.004
Sudden cardiac 
death 340 41,716 0.8 58 14,258 0.4 0.4 (0.2–0.6) 0.49 (0.22–1.08) 0.078
Ablation vs. rate control only
Rate control only (N = 4082) Ablation (N = 3173)
All-cause death 1916 30,188 6.3 342 14,415 2.4 4.0 (3.5–4.4) 0.39 (0.27–0.57) < 0.001
Cardiovascular 
death 933 30,188 3.1 156 14,415 1.1 2.0 (1.7–2.3) 0.35 (0.22–0.56) < 0.001
Heart failure 1180 26,143 4.5 253 13,279 1.9 2.6 (2.2–3.0) 0.36 (0.30–0.44) < 0.001
Stroke/SE 1055 26,492 4.0 286 13,415 2.1 1.9 (1.5–2.2) 0.37 (0.30–0.45) < 0.001
Sudden cardiac 
death 289 29,896 1.0 53 14,329 0.4 0.6 (0.4–0.8) 0.43 (0.21–0.88) 0.020
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4694  | https://doi.org/10.1038/s41598-021-84256-z
www.nature.com/scientificreports/
Reduced heart failure admission and Stroke/SE in ablated patients. AF ablation in heart failure 
patients was related to lower incidence and risk of heart failure admission (2.1 and 4.7 per 100 person-years, 
respectively; HR 0.39, 95% CI 0.33–0.46, p < 0.001) and stroke/SE (2.3 and 3.6 per 100 person-years, respectively; 
HR 0.44, 95% CI 0.37–0.53, p < 0.001) compared to the medical therapy (Table 2). The cumulative incidence of 
A B
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Figure 2.  Weighted cumulative incidence curves of (A) all-cause death and (B) cardiovascular death for 
ablated and medical therapy patients. Figure prepared in R software (version 3.6.1, R Core Team, 2019, Vienna, 
Austria)22.
Event rate of all-cause death
(per 100 person-years) HR (95% CI) p-value p interaction
Ablation Medical therapy
Sex
Female 3.5 7.1 0.55 (0.37-0.84) 0.005 0.652Male 4.7 9.7 0.38 (0.20-0.72) 0.003
Age
<65 years 0.6 2.6 0.28 (0.18-0.43) <0.001 0.0565 years 4.5 9.5 0.47 (0.29-0.76) 0.002
Age
<75 years 1.4 4.2 0.33 (0.24-0.45) <0.001 0.35775 years 7.7 16.0 0.59 (0.31-1.13) 0.109
Hypertension
No 0.4 2.6 0.56 (0.37-0.85) 0.018 0.153Yes 2.9 6.5 0.43 (0.28-0.66) <0.001
Diabetes
No 2.8 5.1 0.47 (0.40-0.55) 0.007 0.130Yes 2.8 9.9 0.29 (0.14-0.57) <0.001
Stroke/TIA
No 1.9 4.7 0.39 (0.29-0.54) <0.001 0.724Yes 4.4 9.6 0.50 (0.26-0.96) 0.038
Vascular disease
No 2.5 5.2 0.44 (0.25-0.76) 0.004 0.628Yes 3.6 8.8 0.43 (0.27-0.67) <0.001
CHA2DS2-VASc score
0-3 0.6 2.4 0.28 (0.18-0.42) <0.001 0.0514 4.1 8.9 0.45 (0.28-0.72) <0.001
Cardioversion or repeated ablation
No 2.9 6.4 0.41 (0.24-0.68) <0.001 0.400Yes 2.5 4.1 0.44 (0.27-0.70) <0.001
OAC rate
<80% 2.1 7.4 0.29 (0.18-0.45) <0.001 <0.00180% 5.3 4.7 0.90 (0.51-1.57) 0.706
Favor ablation Favor medical therapy
0.125     0.25      0.5       1         2 
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heart failure admission (p < 0.001, Fig. 5A) and stroke/SE (p < 0.001, Fig. 5B) in patients with AF ablation was 
significantly lower than those with medical therapy.
The risk of heart failure admission in patients with AF ablation was lower than those treated with AAD (HR 
0.35, 95% CI 0.30–0.42, p < 0.001) and rate control only (HR 0.36, 95% CI 0.30–0.44, p < 0.001). AF ablation was 
also associated with a lower risk of ischemic stroke/SE compared to AAD treatment (HR 0.45, 95% CI 0.37–0.54, 
p < 0.001) and rate control only (HR 0.37, 95% CI 0.30–0.45, p < 0.001) (Table 2).
However, the risk of sudden cardiac death of ablated patients was lower than rate control only patients, but 
not medical therapy or AAD treated patients (Table 2, Fig. 5C).
Event rate of CV death
(per 100 person-years) HR (95% CI) p-value p interaction
Ablation No ablation
Sex
Female 1.9 3.8 0.55 (0.32-0.95) 0.032 0.067Male 0.9 2.5 0.26 (0.12-0.57) <0.001
Age
<65 years 0.3 1.4 0.25 (0.12-0.49) <0.001 0.17765 years 2.0 4.5 0.41 (0.23-0.72) 0.002
Age
<75 years 0.6 2.1 0.29 (0.17-0.48) <0.001 0.38875 years 3.4 7.7 0.49 (0.24-0.96) 0.048
Hypertension
No 0.1 1.0 0.61 (0.21-1.62) 0.128 0.901Yes 1.3 3.2 0.37 (0.22-0.62) <0.001
Diabetes
No 1.0 2.4 0.43 (0.27-0.66) <0.001 0.841Yes 1.8 4.9 0.33 (0.13-0.85) 0.021
Stroke/TIA
No 0.9 2.2 0.41 (0.26-0.65) <0.001 0.800Yes 1.8 4.8 0.38 (0.17-0.83) 0.015
Vascular disease
No 0.6 2.4 0.21 (0.09-0.48) <0.001 0.057Yes 2.8 4.4 0.67 (0.39-1.14) 0.137
CHA2DS2-VASc score
0-3 0.2 1.1 0.19 (0.09-0.43) <0.001 0.0594 1.8 4.4 0.39 (0.23-0.67) <0.001
Cardioversion or repeated ablation
No 1.4 1.3 0.40 (0.22-0.73) 0.003 0.250Yes 0.7 2.7 0.21 (0.11-0.38) <0.001
OAC rate
<80% 1.2 3.5 0.34 (0.18-0.63) <0.001 0.30780% 1.3 2.4 0.45 (0.24-0.84) 0.012
Favor ablation Favor no ablation
0.0625  0.125 0.25  0.5   1      2    
Figure 4.  Subgroup analyses of the risk of cardiovascular death. HR, hazard ratio, TIA, transient ischemic 
attack, OAC, oral anticoagulant.
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Figure 5.  Weighted cumulative incidence curves of (A) heart failure, (B) ischemic stroke/SE, and (C) sudden 
cardiac death for patients with ablation or medical therapy. SE, systemic embolism. Figure prepared in R 
software (version 3.6.1, R Core Team, 2019, Vienna, Austria)22.
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Sensitivity analyses. First, the results using one-to-one propensity score matching (instead of propensity 
score weighting) were consistent with the primary results. HR for all-cause death when AF ablation was per-
formed was 0.38 (95% CI 0.31–0.47, p < 0.001) compared to medical therapy, 0.41 (95% CI 0.34–0.51, p < 0.001) 
compared to AAD treatment, and 0.59 (95% CI 0.45–0.77, p < 0.001) compared to rate control only. In addi-
tion, AF catheter ablation was associated with a lower risk of cardiovascular death, admission for heart failure, 
and ischemic stroke/SE compared to medical therapy, AAD treatment, and rate control in 1:1 propensity score 
matching analysis (Supplementary Table S5). Second, a comparison of the group of patients with heart failure 
who underwent AF ablation and the contemporary matched group of heart failure patients without a history of 
AF is shown in Supplementary Table S6. Compared with propensity score-weighted heart failure patients with-
out a history of AF, the risks of all-cause mortality, admission for heart failure, and ischemic stroke/SE were not 
significantly higher in heart failure patients who underwent AF ablation. Third, AF ablation had no significant 
relationship with any of the falsification endpoints (Supplementary Table S7).
Discussion
The main finding of this study was that in real-world data, ablation for AF in patients with heart failure was 
associated with a significantly lower risk of mortality than medical therapy. Second, AF patients with heart failure 
who underwent ablation had a lower risk of hospitalization for heart failure and stroke/SE than the non-ablated 
matched patients. However, ablation was not associated with the reduced risk of death in the elderly (≥ 75 years) 
and optimally anticoagulated patients. This finding supports the beneficial effect of AF catheter ablation in real-
world AF patients with heart failure.
The effect of ablation on mortality and heart failure admission. Complication rates related to 
the catheter ablation procedure may be higher in patients with heart failure compared with general cohorts 
of patients undergoing an AF ablation. In the CASTLE-AF (Catheter Ablation versus Standard Conventional 
Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation) study, procedure-related com-
plications or serious adverse events occurred in 7.8%15. In the meta-analysis of patients with heart failure, the 
peri-procedural major complication rate of AF catheter ablation was 6.3%24, while the complication rate in a 
contemporary cohort of general patients undergoing AF ablation was 2.3%25. However, consistently in previous 
studies of heart failure patients, AF catheter ablation improved left ventricular systolic function and reduced 
adverse outcomes including readmission due to heart  failure12–14. A randomized control study, the CASTLE-AF 
trial, showed that catheter ablation for AF in patients with heart failure was associated with a significantly lower 
rate of a composite endpoint of death from any cause or hospitalization for worsening heart failure than medi-
cal therapy. Ablation lowered the risk of death with an HR of 0.53 (95% CI 0.32–0.86, p = 0.01)15. In the current 
study, the risk reduction of death in the ablated group compared to the non-ablated group was very similar to 
the improvement in outcome for all-cause mortality in the CASTLE-AF trial.
In contrast to the current study and the CASTLE-AF trial, the AMICA (the Atrial Fibrillation Management 
in Congestive Heart Failure With Ablation) trial, a randomized controlled trial published in 2019, failed to 
show a significant benefit of catheter ablation over best medical  therapy26. However, the AMICA trial included 
only patients with persistent/longstanding persistent AF and heart failure with severely reduced left ventricular 
ejection fraction (LVEF) less than 35%. Our study included not only persistent AF patients but also paroxys-
mal AF patients. Heart failure patients with preserved LVEF also might be included because heart failure was 
defined through the diagnosis code of the administrative database. The limited benefit of catheter ablation in the 
AMICA trial can be explained because study patients were generally sicker and with more advanced heart failure 
compared with the patient in our study. Ablation therapy might have limited benefit over medical treatment in 
patients with seriously advanced heart failure despite achieving a lower AF burden. It should be important to 
select the patient carefully to perform catheter ablation to maximize the benefit of catheter ablation.
In the subgroup analysis of this study, all-cause mortality was not significantly reduced by ablation in the 
elderly population and those with strict anticoagulation. Attenuation of the benefits by ablation in the elderly 
population can also be found in the subgroup analysis of CASTLE-AF and CABANA trial15,16. The more advanced 
left atrial remodeling of older patients and the consequent decrease in AF ablation efficiency may be the cause, 
but this remains unproven. Anticoagulation therapy (vitamin K antagonists) has been shown to reduce overall 
mortality in individuals with AF compared with placebo when all studies are considered together (relative risk, 
0.74; 95% CI, 0.57–0.97)27. No significant reduction of the outcome by ablation in patients with strict anticoagula-
tion emphasizes that effective anticoagulation is the most important to reduce mortality in AF patients with heart 
failure. Catheter ablation for maintaining sinus rhythm is the next important step. The current study suggests that 
ablation might be related to the reduction of cardiovascular mortality in real-world AF patients with heart failure.
The effect of ablation on other outcomes. Ablation also reduced the risk of heart failure hospitaliza-
tion in the CASTLE-AF trial and this  study15. This result highlights the importance of preserving or restoring 
the atrial contribution to cardiac hemodynamics, as the AF catheter ablation rhythm control strategy provides 
additional benefits over simple control of rapid ventricular rate in patients with heart failure in AF.
The number of events of ischemic stroke was too small to have enough power to prove the benefit of ablation 
in the prevention of ischemic stroke in the CASTLE-AF  study15. Several non-randomized observational stud-
ies have reported positive outcomes, including reduced incidence of ischemic stroke and reduced mortality in 
patients with AF  ablation28–31. But, these favorable studies of reducing stroke after ablation have not been per-
formed in specific patients with AF and heart failure. In the current study of AF patients with heart failure, the 
risks of ischemic stroke/SE was lower in patients who underwent AF ablation than those with medical therapy. 
AF and heart failure form a vicious circle with each other. Concomitant AF and heart failure synergistically 
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increase the risk of stroke. Because ablation is an effective treatment for rhythm control that breaks the vicious 
cycle between AF and heart failure, it can be beneficial in stroke prevention of patients with AF and heart failure.
Study limitations. There are several limitations to this study. First, because the administrative database is 
used, it might be susceptible to errors caused by inaccuracies in coding for diagnosis. To minimize these errors, 
we applied definitions already validated in previous studies using the Korean NHIS  data3–5. Second, a retrospec-
tive registry study like ours cannot establish a causal relationship, only the association can be reported. The 
propensity score weighting was used to match the two groups as closely as possible, but unknown confounding 
factors cannot be resolved. Third, because information on the degree of left ventricular function was unavailable, 
the severity of heart failure was not evaluated. Because the healthier people are more likely to receive ablation as 
the Supplement Table S2 shows, the heart failure severity could be different between the ablated group and the 
medical therapy group, which might make bias in the results. Our comparisons between ablation and medical 
therapy should be interpreted carefully. Fourth, Some study patients had a history of hyperthyroidism, hypothy-
roidism, malignancy, chronic obstructive pulmonary disease, or liver disease that may affect outcomes. There-
fore, there may be concerns that the benefit of ablation in AF patients with heart failure may only be applied to 
a specific subgroup. Fifth, the utilization rate of oral anticoagulants in this study was lower than in other studies. 
It is well known that the use of oral anticoagulants in Asia–Pacific countries is low compared to other  regions5,32. 
The utilization rate of oral anticoagulants has improved with the introduction of non-vitamin K antagonist oral 
anticoagulants (NOACs). However, in Korea, the use of NOACs was increased from 2015 as NOACs were fully 
reimbursed by the national insurance system. The inclusion period of our study was from 2005 to 2015, before 
NOAC was fully used. So oral anticoagulants were underused in this study population and a large proportion of 
oral anticoagulants was warfarin. The underuse of oral anticoagulants and a large proportion of warfarin among 
oral anticoagulants may have influenced the results of this study. Sixth, the dose and label adherence of NOACs 
was not evaluated. And we also did not have access to information on time-in-therapeutic range in patients using 
warfarin. Lack of information about the quality of oral anticoagulants treatment might interfere with results, 
especially the outcome of ischemic stroke and systemic embolism. Finally, to indirectly assess the relationship 
between successful rhythm control by ablation and all-cause and cardiovascular death, subgroup analysis was 
performed according to “Cardioversion or repeated ablation” as an indicator of AF recurrence after ablation. 
However, the exact relationships between the primary outcome or mortality and rhythm control statuses such 
as sinus rhythm maintenance or AF burden were not evaluated. Moreover, since there is no continuous rhythm 
monitoring data, the subclinical or asymptomatic AF recurrence can not be assessed.
Conclusion
Ablation may be associated with lower incidences of death, heart failure admission, and stroke/SE in real-world 
AF patients with heart failure, supporting the role of AF ablation in heart failure.
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